Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10 ...Middle East

SHANGHAI, Feb. 21, 2025 /PRNewswire/ -- Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued collaboration with Mabgeek in advancing MG-K10, a potential Best-in-Class therapy, a novel IL-4Rα-targeting antibody drug for...

Read More Details
Finally We wish PressBee provided you with enough information of ( Chime Biologics Supports Mabgeek to Enter the U.S. Phase III Trials for MG-K10 )

Also on site :

• The 36 US bases on the frontline of Iranian retribution
• NATO leaders gather Tuesday for what could be a historic summit, or one marred by divisions
• SMB-focused Finom closes €115M as European fintech heats up